Resumen
INTRODUCCIÓN: el linfoma primario del sistema nervioso central (LPSNC) corresponde a una causa de importante mortalidad dentro de los tumores primarios del sistema nervioso central, además existen pocos datos epidemiológicos actualmente, razón por la cual se decide hacer un reporte de casos en el grupo de neuropatología de la Universidad de Antioquia.
OBJETIVO: describir el comportamiento de esta patología en un grupo de pacientes.
MATERIALES Y MÉTODOS: se revisaros los estudios patológicos e historias clínicas de 12 pacientes con diagnóstico de LPSNC en el servicio de neuropatología de la Universidad de Antioquia 2004 el 2011.
RESUTADOS: se encontraron 12 pacientes que cumplían el criterio de inclusión. De estos pacientes el 61.5% fueron hombres y el 38.5% mujeres. La edad promedio al momento del diagnóstico fue de 42.6 años (1- 77 años). El Linfoma B no hodking de células gigantes con patrón difuso fue el tumor más frecuente con un 83.3 %, 8.35% corresponde a linfoma de células T, 8.35% a Linfoma de Burkitt; 33.3 % corresponden a pacientes inmunode-ficientes.
CONCLUSIÓN: en esta serie de pacientes con linfoma del sistema nervioso central se encontraron características clínicas similares a las encontradas en la literatura, quizás el único hallazgo disímil fue la mayor cantidad de pacientes sin aparente alteración en el sistema inmune.
Citas
BAILEY P. Intracranial sarcomatous tumors of lep-tomeningeal origin. Arch Surg. 1929;18:1359-402.
HOFFMAN S, PROPP JM, MCCARTHY BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol 2006;8:27-37.
SCHABET M. Epidemiology of primary CNS lymphoma. J Neurooncol. 1999;43:199-201.
BHAGAVATHI S, WILSON JD. Primary central nervous system lymphoma. Arch Pathol Lab Med. 2008;132:1830-1834.
FLINN IW, AMBINDER RF. AIDS primary central nervous system lymphoma. Curr Opin Oncol. 1996;8:373-376.
BERAL V, PETERMAN T, BERKELMAN R, JAFFE H. AIDS-associated non-Hodgkin lymphoma. Lancet. 1991;337:805-809.
MACMAHON EM, GLASS JD, HAYWARD SD, MANN RB, BECKER PS, CHARACHE P, ET AL. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet. 1991;338:969-973.
PANAGEAS KS, ELKIN EB, DEANGELIS LM, BEN-PORAT L, ABREY LE. Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis. Cancer. 2005;104:2466-2472.
FINE HA, MAYER RJ. Primary central nervous system lymphoma. Ann Intern Med. 1993;119:1093- 1104.
MILLER DC, HOCHBERG FH, HARRIS NL, GRUBER ML, LOUIS DN, COHEN H. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer. 1994;74:1383-1397.
SMITH JR, BRAZIEL RM, PAOLETTI S, LIPP M, UGUCCIONI M, ROSENBAUM JT. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood. 2003;101:815-821.
KADOCH C, TRESELER P, RUBENSTEIN JL. Molecular pathogenesis of primary central nervous system lymphoma. Neurosurg Focus. 2006;21:E1.
JIANG L, MARLOW LA, COOPER SJ, ROEMEL-ING CV, MENKE DM, COPLAND JA, ET AL. Selective central nervous system tropism of primary central nervous system lymphoma. Int J Clin Exp Pathol. 2010;3:763-767.
GORMLEY RP, MADAN R, DULAU AE, XU D, TAMAS EF, BHATTACHARYYA PK, ET AL. Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases. Am J Clin Pathol. 2005;124:790-798.
SHEARER GM. HIV-induced immunopathogen-esis. Immunity. 1998;9:587-593.
BIANCOTTO A, GRIVEL JC, IGLEHART SJ, VANPOUILLE C, LISCO A, SIEG SF, ET AL. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood. 2007;109:4272-4279.
KHATRI VP, BAIOCCHI RA, BERNSTEIN ZP, CALIGIURI MA. Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer. Cancer J Sci Am. 1997;3 (Suppl 1):S129-136.
MOSES AV, WILLIAMS SE, STRUSSENBERG JG, HENEVELD ML, RUHL RA, BAKKE AC, ET AL. HIV-1 induction of CD40 on endothelial cells promotes the outgrowth of AIDS-associated B-cell lymphomas. Nat Med. 1997;3:1242-1249.
CHIRIVI RG, TARABOLETTI G, BANI MR, BARRA L, PICCININI G, GIACCA M, ET AL. Human immunodeficiency virus-1 (HIV-1)-Tat protein promotes migration of acquired immunodeficiency syndrome-related lymphoma cells and enhances their adhesion to endothelial cells. Blood. 1999;94:1747-1754.
AOKI Y, TOSATO G. Targeted inhibition of angiogenic factors in AIDS-related disorders. Curr Drug Targets Infect Disord. 2003;3:115-128.
HAMILTON-DUTOIT SJ, PALLESEN G, KARKOV J, SKINHOJ P, FRANZMANN MB, PED-ERSEN C. Identification of EBV-DNA in tumour cells of AIDS-related lymphomas by in-situ hybridisation. Lancet. 1989;1:554-552.
OMETTO L, MENIN C, MASIERO S, BONALDI L, DEL MISTRO A, CATTELAN AM, ET AL. Molecular profile of Epstein-Barr virus in human immunodeficiency virus type 1-related lymphadenopathies and lymphomas. Blood. 1997;90:313-322.
MITTRA RA, PULIDO JS, HANSON GA, KAJ-DACSY-BALLA A, BRUMMITT CF. Primary ocular Epstein-Barr virus-associated non-Hodgkin's lymphoma in a patient with AIDS: a clinicopathologic report. Retina. 1999;19:45-50.
GUTERMAN KS, HAIR LS, MORGELLO S. Epstein-Barr virus and AIDS-related primary central nervous system lymphoma. Viral detection by immunohistochemistry, RNA in situ hybridization, and polymerase chain reaction. Clin Neuropathol. 1996;15:79-86.
KERSTEN MJ, KLEIN MR, HOLWERDA AM, MIEDEMA F, VAN OERS MH. Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma. J Clin Invest. 1997;99:1525-1533.
VAN BAARLE D, HOVENKAMP E, CALLAN MF, WOLTHERS KC, KOSTENSE S, TAN LC, ET AL. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood. 2001;98:146-155.
BIGGAR RJ, CHATURVEDI AK, GOEDERT JJ, ENGELS EA. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007;99:962-972.
PELICCI PG, KNOWLES DM, 2ND, ARLIN ZA, WIECZOREK R, LUCIW P, DINA D, ET AL. Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis. J Exp Med. 1986;164:2049-2060.
CINGOLANI A, DE LUCA A, LAROCCA LM, AMMASSARI A, SCERRATI M, ANTINORI A, ET AL. Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. J Natl Cancer Inst. 1998;90:364-369.
BATAILLE B, DELWAIL V, MENET E, VAN-DERMARCQ P, INGRAND P, WAGER M, ET AL. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 2000;92:261-266.
LEE DK, CHUNG CK, KIM HJ, KIM K, CHOE G, MOON CW, ET AL. Multifocal primary CNS T cell lymphoma of the spinal cord. Clin Neuropathol. 2002;21:149-155.
HERRLINGER U, WELLER M, KUKER W. Primary CNS lymphoma in the spinal cord: clinical manifestations may precede MRI detectability. Neuroradiology. 2002;44:239-244.
NAKAMIZO T, INOUE H, UDAKA F, ODA M, KAWAI M, UEMURA K, ET AL. Magnetic resonance imaging of primary spinal intramedullary lymphoma. J Neuroimaging. 2002;12:183-186.
ALBANESE V, PLATANIA N. Spinal intradural extramedullary tumors. Personal experience. J Neuro-surg Sci. 2002;46:18-24.
HERAN NS, YONG RL, HERAN MS, YIP S, FAIRHOLM D. Primary intradural extraarachnoid hodgkin lymphoma of the cervical spine. Case report. J Neurosurg Spine. 2006;5:61-64.
YAMASHITA T, SAKAURA H, OSHIMA K, IWASAKI M, YOSHIKAWA H. Solitary intradural extramedullary lymphoma of the cervical spine. J Neurosurg Spine. 2010;12:436-439.
LACHANCE DH, O'NEILL BP, MACDONALD DR, JAECKLE KA, WITZIG TE, LI CY, ET AL. Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature. Neurology. 1991;41:95-100.
MATANO S, SAKASHITA Y, FURUSHO H, OHASHI M, TERAHATA S, KAKUMA K, ET AL. Primary leptomeningeal lymphoma. J Neurooncol. 2001;52:81-83.
GROVE A, VYBERG M. Primary leptomeningeal T-cell lymphoma: a case and a review of primary T-cell lymphoma of the central nervous system. Clin Neuropathol. 1993;12:7-12.
HORMIGO A, ABREY L, HEINEMANN MH, DEANGELIS LM. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol. 2004;126:202-208.
PARK S, ABAD S, TULLIEZ M, MONNET D, MERLAT A, GYAN E, ET AL. Pseudouveitis: a clue to the diagnosis of primary central nervous system lymphoma in immunocompetent patients. Medicine (Baltimore). 2004;83:223-232.
GRIMM SA, MCCANNEL CA, OMURO AM, FERRERI AJ, BLAY JY, NEUWELT EA, ET AL. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology. 2008;71:1355-1360.
MERLE-BERAL H, DAVI F, CASSOUX N, BAUDET S, COLIN C, GOURDET T, ET AL. Biological diagnosis of primary intraocular lymphoma. Br J Haematol. 2004;124:469-473.
BAEHRING JM, DAMEK D, MARTIN EC, BETENSKY RA, HOCHBERG FH. Neurolympho-matosis. Neuro Oncol. 2003;5:104-115.
GRISARIU S, AVNI B, BATCHELOR TT, VAN DEN BENT MJ, BOKSTEIN F, SCHIFF D, ET AL. Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2010;115:5005-5011.
KHONG P, PITHAM T, OWLER B. Isolated neurolymphomatosis of the cauda equina and filum terminale: case report. Spine (Phila Pa 1976). 2008;33:E807-811.
LEVIN N, SOFFER D, GRISSARU S, AIZIKOV-ICH N, GOMORI JM, SIEGAL T. Primary T-cell CNS lymphoma presenting with leptomeningeal spread and neurolymphomatosis. J Neurooncol. 2008;90:77-83.
ABREY LE, BATCHELOR TT, FERRERI AJ, GOSPODAROWICZ M, PULCZYNSKI EJ, ZUCCA E, ET AL. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034-5043.
MOHILE NA, DEANGELIS LM, ABREY LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol. 2008;10:223-228.
HOCHBERG FH, MILLER DC. Primary central nervous system lymphoma. J Neurosurg. 1988;68:835-853.
DIAZ-CANO S. PCR-based alternative for diagnosis of immunoglobulin heavy chain gene rearrangement: principles, practice, and polemics. Diagn Mol Pathol. 1996;5:3-9.
EKSTEIN D, BEN-YEHUDA D, SLYU-SAREVSKY E, LOSSOS A, LINETSKY E, SIEGAL T. CSF analysis of IgH gene rearrangement in CNS lymphoma: relationship to the disease course. J Neurol Sci. 2006;247:39-46.
PELS H, MONTESINOS-RONGEN M, SCHALLER C, SCHLEGEL U, SCHMIDT-WOLF IG, WIESTLER OD, ET AL. VH gene analysis of primary CNS lymphomas. J Neurol Sci. 2005;228:143-147.
KUKER W, NAGELE T, KORFEL A, HECKL S, THIEL E, BAMBERG M, ET AL. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005;72:169-177.
ZHANG D, HU LB, HENNING TD, RAVARANI EM, ZOU LG, FENG XY, ET AL. MRI findings of primary CNS lymphoma in 26 immunocompetent patients. Korean J Radiol. 2010;11:269-277.
JENKINS CN, COLQUHOUN IR. Characterization of primary intracranial lymphoma by computed tomography: an analysis of 36 cases and a review of the literature with particular reference to calcification haemorrhage and cyst formation. Clin Radiol.1998;53:428-434.
BUHRING U, HERRLINGER U, KRINGS T, THIEX R, WELLER M, KUKER W. MRI features of primary central nervous system lymphomas at presentation. Neurology. 2001;57:393-396.
ARORA A, KAPOOR A, SHARMA A. Correspondence re: MRI findings of primary CNS lymphoma in 26 immunocompetent patients. Korean J Radiol. 2010;11:702-703.
ZACHARIA TT, LAW M, NAIDICH TP, LEEDS NE. Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectros-copy. JNeuroimaging. 2008;18:411-417.
ABREY LE, BEN-PORAT L, PANAGEAS KS, YAHALOM J, BERKEY B, CURRAN W, ET AL. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711-5715.
FERRERI AJ, BLAY JY, RENI M, PASINI F, SPINA M, AMBROSETTI A, ET AL. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266-272.
BESSELL EM, GRAUS F, LOPEZ-GUILLERMO A, LEWIS SA, VILLA S, VERGER E, ET AL. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys. 2004;59:501-508.
FERRACINI R. (Primary malignant non-Hodg-kin's lymphomas of the central nervous system in immunocompetent patients: diagnostic, prognostic and therapeutic criteria). Pathologica. 1997;89:146-154.
MATHEW BS, CARSON KA, GROSSMAN SA. Initial response to glucocorticoids. Cancer. 2006;106:383-387.
MORRIS PG, ABREY LE. Therapeutic challenges in primary CNS lymphoma. LancetNeurol. 2009;8:581-592.
BATCHELOR T, CARSON K, O'NEILL A, GROSSMAN SA, ALAVI J, NEW P, ET AL. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21:1044-1049.
HOANG-XUAN K, TAILLANDIER L, CHINOT O, SOUBEYRAN P, BOGDHAN U, HILDEBRAND J, ET AL. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treat-merit of Cancer Brain Tumor Group. J Clin Oncol. 2003;21:2726-2731.
O'BRIEN P, ROOS D, PRATT G, LIEW K, BARTON M, POULSEN M, ET AL. Phase II multi-center study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol. 2000;18:519-526.
HERRLINGER U, SCHABET M, BRUGGER W, KORTMANN RD, KUKER W, DECKERT M, ET AL. German Cancer Society Neuro-Oncol-ogy Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol. 2002;51:247-252.
PELS H, SCHMIDT-WOLF IG, GLASMACHER A, SCHULZ H, ENGERT A, DIEHL V, ET AL. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraven-tricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21:4489-4495.
FERRERI AJ, RENI M, FOPPOLI M, MARTELLI M, PANGALIS GA, FREZZATO M, ET AL. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374:1512-1520.
WONG ET, TISHLER R, BARRON L, WU JK. Immunochemotherapy with rituximab and temo-zolomide for central nervous system lymphomas. Cancer. 2004;101:139-145.
ENTING RH, DEMOPOULOS A, DEANGELIS LM, ABREY LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology. 2004;63:901-903.
Wong ET. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temo-zolomide. Neurology. 2005;64:934.
SANTISTEBAN M, NIETO Y, DE LA CRUZ S, ARISTU J, ZUBIETA JL, FERNANDEZ HIDALGO O. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule. Clin Transl Oncol. 2007;9:465-467.
NELSON DF, MARTZ KL, BONNER H, NELSON JS, NEWALL J, KERMAN HD, ET AL. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23:9-17.
FERRERI AJ, ABREY LE, BLAY JY, BORISCH B, HOCHMAN J, NEUWELT EA, ET AL. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol. 2003;21:2407-2414.
JOHNSON BA, FRAM EK, JOHNSON PC, JACOBOWITZ R. The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. AJNR Am J Neuroradiol. 1997;18:563-572.
FORSYTH PA, DEANGELIS LM. Biology and management of AIDS-associated primary CNS lymphomas. Hematol Oncol Clin North Am. 1996;10:1125-1134.
RAEZ LE, PATEL P, FEUN L, RESTREPO A, RAUB WA, JR., CASSILETH PA. Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL). Crit Rev Oncog. 1998;9:199-208.
BAUMGARTNER JE, RACHLIN JR, BECK-STEAD JH, MEEKER TC, LEVY RM, WARA WM, ET AL. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg. 1990;73:206-211.
SKOLASKY RL, DAL PAN GJ, OLIVI A, LENZ FA, ABRAMS RA, MCARTHUR JC. HIV-associated primary CNS lymorbidity and utility of brain biopsy. J Neurol Sci. 1999;163:32-38.
FORSYTH PA, YAHALOM J, DEANGELIS LM. Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology. 1994;44:1473-1479.
CORN BW, DONAHUE BR, ROSENSTOCK JG, COOPER JS, XIE Y, BRANDON AH, ET AL. Palliation of AIDS-related primary lymphoma of the brain: observations from a multi-institutional database. Int J Radiat Oncol Biol Phys. 1997;38:601-605.
DEMARIO MD, LIEBOWITZ DN. Lymphomas in the immunocompromised patient. Semin Oncol. 1998;25:492-502.
SKIEST DJ, CROSBY C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS. 2003;17:1787-1793.
NEWELL ME, HOY JF, COOPER SG, DEGRAAFF B, GRULICH AE, BRYANT M, ET AL. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer. 2004;100:2627-2636.
PAJONK F, MCBRIDE WH. Survival of AIDS patients with primary central nervous system lymphoma may be improved by the radiosensitizing effects of highly active antiretroviral therapy. AIDS. 2002;16:1195-1196.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.